223 related articles for article (PubMed ID: 37575237)
21. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
22. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
Front Immunol; 2021; 12():628966. PubMed ID: 33664747
[TBL] [Abstract][Full Text] [Related]
23. S100A10 Is a New Prognostic Biomarker Related to the Malignant Molecular Features and Immunosuppression Process of Adult Gliomas.
Ma K; Chen S; Chen X; Yang C; Yang J
World Neurosurg; 2022 Sep; 165():e650-e663. PubMed ID: 35779750
[TBL] [Abstract][Full Text] [Related]
24. CD44-Mediated Poor Prognosis in Glioma Is Associated With M2-Polarization of Tumor-Associated Macrophages and Immunosuppression.
Xiao Y; Yang K; Wang Z; Zhao M; Deng Y; Ji W; Zou Y; Qian C; Liu Y; Xiao H; Liu H
Front Surg; 2021; 8():775194. PubMed ID: 35187044
[TBL] [Abstract][Full Text] [Related]
25. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
26. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
[TBL] [Abstract][Full Text] [Related]
27. The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy.
Wang Z; Liu Y; Mo Y; Zhang H; Dai Z; Zhang X; Ye W; Cao H; Liu Z; Cheng Q
Front Immunol; 2021; 12():731751. PubMed ID: 34603309
[TBL] [Abstract][Full Text] [Related]
28. Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker FAM111A in Diffuse Lower-Grade Glioma.
Ji X; Ding F; Gao J; Huang X; Liu W; Wang Y; Liu Q; Xin T
Front Oncol; 2020; 10():573800. PubMed ID: 33194678
[TBL] [Abstract][Full Text] [Related]
29. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
30. Immune and Clinical Features of
Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F
Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752
[TBL] [Abstract][Full Text] [Related]
31. Multi-omics analysis reveals the involvement of origin recognition complex subunit 6 in tumor immune regulation and malignant progression.
Zhu J; Chen Q; Zeng L; Gao H; Wu T; He Y; Xu J; Pang J; Peng J; Deng Y; Han Y; Yi W
Front Immunol; 2023; 14():1236806. PubMed ID: 37901236
[TBL] [Abstract][Full Text] [Related]
32. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.
Jiang Y; Ji Q; Long X; Wang P; Tu Z; Zhang X; Zhu X; Huang K; Li J
Front Immunol; 2022; 13():810832. PubMed ID: 35265072
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
34. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of RAB34 associates with tumor aggressiveness and immune infiltration in glioma.
Hou P; Wan Q; Wang Q; Wu X; Lu X
Biosci Rep; 2022 Oct; 42(10):. PubMed ID: 36222286
[TBL] [Abstract][Full Text] [Related]
36. Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.
Li G; Wang Z; Zhang C; Liu X; Cai J; Wang Z; Hu H; Wu F; Bao Z; Liu Y; Zhao L; Liang T; Yang F; Huang R; Zhang W; Jiang T
Oncoimmunology; 2017; 6(8):e1328339. PubMed ID: 28919992
[No Abstract] [Full Text] [Related]
37. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y
Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523
[TBL] [Abstract][Full Text] [Related]
38. Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
Yuan Y; Zhao Q; Zhao S; Zhang P; Zhao H; Li Z; Du Y; Tian X; Lu J
Cancer Med; 2019 Jul; 8(8):3811-3821. PubMed ID: 31140757
[TBL] [Abstract][Full Text] [Related]
39. Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma.
Zou CY; Guan GF; Zhu C; Liu TQ; Guo Q; Cheng W; Wu AH
CNS Neurosci Ther; 2019 Mar; 25(3):333-342. PubMed ID: 30105842
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
